- Coordinator
- Universitat De Barcelona, Spain
- Runs
- 1 June 2026 to 31 May 2028
- Status
- Running
- EU funding
- €194k
- Total cost
- —
- Partners
- 3 organisations in 3 countries
- Type
- Marie Skłodowska-Curie Action
- Grant agreement
- 101206507
What the project is doing
In the project's own words, from its summary on CORDIS.
SELECT-IT aims to develop small molecules that specifically target bacterial intramolecular trans(IT)-sialidases. IT-sialidases from Ruminococcus species have been related to progression of inflammatory bowel diseases (IBD) and colorectal cancer (CRC). Following elucidation of the yet unknown mechanisms of action of IT-sialidases, I will rationally design candidate inhibitors, synthesise and characterise them, and assess their binding modes, inhibition efficacy and target selectivity.
Inspired by strategies previously successful for antiviral drugs like Tamiflu, SELECT-IT will modify existing molecules such as Siastatin B, DANA, and 2,7-anhydro-Neu5Ac, as starting points to develop candidates that selectively inhibits bacterial sialidases while sparing human ones. The inhibitors will undergo systematic refinement through computer simulation (molecular dynamics, QM/MM and metadynamics) and experimental techniques (biochemical assays and NMR spectroscopy) to ensure high specificity.
SELECT-IT aims to develop targeted inhibitors for managing bacterial infections linked to IBD and CRC, contributing directly to the creation of new therapeutic options.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Universitat De Barcelona | Barcelona | Spain | Coordinator |
| Universita Degli Studi Di Napoli Federico Ii | Napoli | Italy | Associatedpartner |
| Universiteit Leiden | Leiden | Netherlands | Associatedpartner |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI